Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Hologic Inc Reaffirms FY 2013 Guidance-Conference Call
Hologic Inc announced that for fiscal 2013, it expects revenue to be in the range of $2.61 billion to $2.64 billion and earnings per share (EPS) in the range of $1.56 to $1.58. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.63 billion and EPS of $1.58 for fiscal 2013.
Latest Developments for Hologic Inc
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Hologic Inc Updates FY 2013 Guidance To A Range In Line With Analysts' Estimates-Conference Call
- Hologic Inc Issues Q3 2013 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance
- Hologic Inc Completes Sale of LIFECODES to Immucor
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this
Follow Reuters